REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
01/05/2026
Back to search
Official data from USPTO
IOMX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
51
Latest update
01/06/2026
Classification
Registered
Trademark type
Word
Nice classes
5, 10, 42
Filing date
02/19/2018
Registration date
01/05/2021
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/05/2021
Last transaction
01/06/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
99
Owner location
Planegg/Martinsried, DE
Examiner
WATTS-FITZGERALD,CAITLIN C
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
IOmx Therapeutics AG
Representatives
Allison R. Imber Allen, Dyer, Doppelt & Gilchrist, P.A.
Technical classification
Nice Classes
Class 5Class 10Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticalsmedical and veterinary preparationspharmaceutical preparations and formulationsmedicated health preparationsall of the aforesaid goods for use in the treatment or prevention of human and animal diseasesdisorders and conditionscirculatoryrespiratoryendocrineneurologiccardiovascularalimentarypulmonarymusculoskeletallymphatic or gastrointestinal diseasesdisorders and conditionsfor use in the treatment or prevention of complications associated with such diseasesdisorders and conditions; Pharmaceuticalsmedical and veterinary preparationspharmaceutical preparations and formulationsmedicated health preparationsall of the aforesaid goods for use in the treatment or prevention of human and animal diseasesdisorders and conditionsbone sensoryviralurinaryrenalmetabolic or central nervous system diseasesdisorders and conditionsfor use in the treatment or prevention of complications associated with such diseasesdisorders and conditions; Pharmaceuticalsmedical and veterinary preparationspharmaceutical preparations and formulationsmedicated health preparationsall of the aforesaid goods for use in the treatment or prevention of human and animal diseasesdisorders and conditionsinfectiousauto-immune or immune-relatedcell-proliferative or oncologic diseasesdisorders and conditionscancerstumours and metastasesfor use in the treatment or prevention of complications associated with such diseasesdisorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseasesdisorders and conditionscirculatoryrespiratoryendocrineneurologiccardiovascularalimentarypulmonarymusculoskeletallymphatic or gastrointestinal diseasesdisorders and conditionsfor the diagnosis or prognosis of complications associated with such diseasesdisorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseasesdisorders and conditionsbone sensoryviralurinaryrenalmetabolic or central nervous system diseasesdisorders and conditionsfor the diagnosis or prognosis of complications associated with such diseasesdisorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseasesdisorders and conditionsinfectiousauto-immune or immune-relatedcell-proliferative or oncologic diseasesdisorders and conditionscancerstumours and metastasesfor the diagnosis or prognosis of complications associated with such diseasesdisorders and conditions
Class 10
Diagnostic apparatus for the diagnosis or prognosis of human and animal diseasesdisorders and conditionscirculatoryrespiratoryendocrineneurologiccardiovascularalimentarypulmonarymusculoskeletallymphatic or gastrointestinal diseasesdisorders and conditionsfor the diagnosis or prognosis of complications associated with such diseasesdisorders and conditionsspecificallysample-analysis devices and related data-analysis software sold as a unitnucleic acid-analysis or protein-analysis diagnosis apparatusdiagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit; Diagnostic apparatus for the diagnosis or prognosis of human and animal diseasesdisorders and conditionsbone sensoryviralurinaryrenalmetabolic or central nervous system diseases disorders and conditionsfor the diagnosis or prognosis of complications associated with such diseasesdisorders and conditionsspecificallysample-analysis devices and related data-analysis software sold as a unitnucleic acid-analysis or protein-analysis diagnosis apparatusdiagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit; Diagnostic apparatus for the diagnosis or prognosis of human and animal diseasesdisorders and conditionsinfectiousauto-immune or immune-relatedcell-proliferative or oncologic diseasesdisorders and conditionscancerstumours and metastasesfor the diagnosis or prognosis of complications associated with such diseasesdisorders and conditionsspecificallysample-analysis devices and related data-analysis software sold as a unitnucleic acid-analysis or protein-analysis diagnosis apparatusdiagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit
Class 42
Scientific servicesscientific researchanalysis and testing in the fields of biologychemistry or medicineas well as in the fields of immunologyoncologymolecular biologycellular biologybiochemistry and medicinal chemistry; Scientific servicesscientific researchanalysis and testing in the fields of discovery and development of pharmaceuticalsmedical and veterinary preparationsdiagnostic preparations and biomarker reagentsdiagnostic apparatus; Design and development of computer software for database managementcloud-storage of datadata-managementdata-querydata-analysis and data-presentationfor the queryanalysis and presentation of the sequence or structure of moleculesfor predicting or providing a medical diagnosis or prognosisas well as for controlling and managing patient medical informationwith any of the aforementioned services for use in the fields of biologychemistry or medicineas well as for use in the fields of immunologyoncologymolecular biologycellular biologybiochemistry and medicinal chemistry; Design and development of computer software for database managementcloud-storage of datadata-managementdata-querydata-analysis and data-presentationas well as for the queryanalysis and presentation of the sequence or structure of moleculesfor predicting or providing a medical diagnosis or prognosiswith any of the aforementioned services for use in the fields of discovery and development of pharmaceuticalsmedical and veterinary preparationsdiagnostic preparations and biomarker reagentsdiagnostic apparatus
Publications
History of USPTO decisions and trademark events.
51 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/08/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
02/08/2024
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
02/08/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/08/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/08/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/08/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/08/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/06/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/06/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
03/06/2023
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
03/06/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/06/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/06/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/06/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/08/2021
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
10/08/2021
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
10/08/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/08/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/08/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
01/05/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/20/2020
PUBO
PUBLISHED FOR OPPOSITION
10/20/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/30/2020
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
09/15/2020
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
09/11/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/10/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/25/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/24/2020
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
08/24/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
07/09/2020
GNFR
FINAL REFUSAL E-MAILED
07/09/2020
CNFR
FINAL REFUSAL WRITTEN
07/09/2020
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
06/24/2020
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
12/18/2019
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
06/18/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
12/12/2018
GNSL
LETTER OF SUSPENSION E-MAILED
12/12/2018
CNSL
SUSPENSION LETTER WRITTEN
12/12/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/10/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/10/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/03/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/04/2018
GNRT
NON-FINAL ACTION E-MAILED
06/04/2018
CNRT
NON-FINAL ACTION WRITTEN
06/04/2018
DOCK
ASSIGNED TO EXAMINER
06/04/2018
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
04/03/2018
ALIE
ASSIGNED TO LIE
03/30/2018
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
03/16/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/26/2018
NWAP
NEW APPLICATION ENTERED
02/22/2018
Continuous trademark protection
Get notified about every new filing that threatens IOMX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.